Enterprise Value
10.87B
Cash
1.823B
Avg Qtr Burn
N/A
Short % of Float
4.54%
Insider Ownership
2.78%
Institutional Own.
95.90%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
EPIDIOLEX® (cannabidiol) Details Epilepsy, Dravet syndrome, Tuberous sclerosis complex, Lennox-Gastaut syndrome | Approved Quarterly sales | |
Zepzelca (Lurbinectedin) Details Cancer, Small cell lung cancer | Approved Quarterly sales | |
Rylaze /Enrylaze (JZP-458) Details Acute lymphoblastic leukemia | Approved Quarterly sales | |
Xywav (JZP-258) (oxybate salts) Details EDS in Idiopathic Hypersomnia
| Approved Quarterly sales | |
Zanidatamab Details HER2-expressing cancers, Cancer, Biliary Tract Cancer | PDUFA Approval decision | |
EPIDIOLEX® (cannabidiol) Details Rare diseases, Neurological disorder, Rare genetic disease, Epilepsy, Seizures | Phase 3 Data readout | |
Zepzelca +Tecentriq Details Cancer, Small cell lung cancer | Phase 3 Data readout | |
Suvecaltamide (JZP-385) Details Essential tremor | Phase 2b Update | |
Suvecaltamide (JZP-385) Details Parkinson's disease | Phase 2 Data readout | |
Zepzelca (Lurbinectedin) Details Cancer, Solid tumor/s | Phase 2 Data readout | |
CBDV (Cannabidivarin /GWP42006) Details Epilepsy, Autism spectrum disorders | Phase 2 Data readout | |
Zanidatamab combo w/ chemo Details HER2-expressing cancers, Cancer, Gastroesophageal adenocarcinomas | Phase 2 Data readout | |
Zanidatamab + Palbociclib + Fulvestrant Details Cancer, ER+/HER2- breast cancer | Phase 2a Data readout | |
Zepzelca (Lurbinectedin) Details Solid tumor/s, Cancer, Endometrial cancer | Phase 1/2 Data readout | |
Zanidatamab combo w/ docetaxel Details Cancer, HER2-expressing cancers | Phase 1/2 Interim update | |
JZP351 (CPX-351) Details Acute myeloid leukemia, Blood cancer, Cancer | Phase 1b Data readout | |
Zanidatamab Details Cancer, Breast cancer | Phase 1 Data readout | |
JZP815 Details Solid tumor/s, Cancer | Phase 1 Data readout | |
JZP441 (orexin-2 receptor agonist) Details Sleeping disorder, EDS in Idiopathic Hypersomnia
, Narcolepsy | Phase 1 Update | |
JZP898 Details Solid tumor/s, Cancer | Phase 1 Initiation | |
Nabiximols Details Multiple sclerosis | Failed Discontinued | |
JZP-150 (FAAH inhibitor) Details Post-traumatic stress disorder | Failed Discontinued | |
EPIDIOLEX® (cannabidiol) Details Rare diseases, Rare genetic disease, Rett syndrome, Neurological disorder | Failed Discontinued |